Kolon TissueGene (A950160) Stock Overview
Develops cell therapies for orthopedic diseases and other unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
A950160 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kolon TissueGene, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩72,900.00 |
| 52 Week High | ₩88,700.00 |
| 52 Week Low | ₩27,250.00 |
| Beta | -0.91 |
| 1 Month Change | -10.22% |
| 3 Month Change | 63.09% |
| 1 Year Change | 154.45% |
| 3 Year Change | 611.22% |
| 5 Year Change | n/a |
| Change since IPO | 70.73% |
Recent News & Updates
Kolon TissueGene (KOSDAQ:950160) Has Debt But No Earnings; Should You Worry?
Nov 29
Is Kolon TissueGene (KOSDAQ:950160) Using Too Much Debt?
Jun 26Shareholder Returns
| A950160 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.4% | 6.0% | 5.8% |
| 1Y | 154.5% | 53.1% | 76.0% |
Return vs Industry: A950160 exceeded the KR Biotechs industry which returned 53.1% over the past year.
Return vs Market: A950160 exceeded the KR Market which returned 76% over the past year.
Price Volatility
| A950160 volatility | |
|---|---|
| A950160 Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A950160's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A950160's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Moon-Jong Noh | www.tissuegene.com |
Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine.
Kolon TissueGene, Inc. Fundamentals Summary
| A950160 fundamental statistics | |
|---|---|
| Market cap | ₩6.13t |
| Earnings (TTM) | -₩87.46b |
| Revenue (TTM) | ₩5.08b |
Is A950160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950160 income statement (TTM) | |
|---|---|
| Revenue | ₩5.08b |
| Cost of Revenue | ₩4.44b |
| Gross Profit | ₩637.42m |
| Other Expenses | ₩88.09b |
| Earnings | -₩87.46b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05k |
| Gross Margin | 12.56% |
| Net Profit Margin | -1,722.65% |
| Debt/Equity Ratio | 38.4% |
How did A950160 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/12 16:09 |
| End of Day Share Price | 2026/01/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kolon TissueGene, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Haejoo Wi | Korea Investment & Securities Co., Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |